Latisse vs Careprost: Is the Generic Bimatoprost Identical to the Brand?

✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

The Latisse story is one of pharmaceutical-industry serendipity. Bimatoprost 0.03% ophthalmic solution was FDA-approved in 2001 as Lumigan, a once-daily eye drop for the treatment of elevated intraocular pressure in open-angle glaucoma. Within a few years, prescribing ophthalmologists noticed an unexpected side effect: patients using Lumigan reported their eyelashes growing thicker, longer, and darker on the treated eye. The cosmetic effect was substantial enough that Allergan reformulated the same molecule at the same concentration for eyelash application and obtained FDA approval as Latisse in December 2008 for “hypotrichosis of the eyelashes” (inadequate or sparse eyelashes).

The Yoelin et al. pivotal trial (Dermatologic Surgery, 2010¹) randomised 278 adults with hypotrichosis to once-daily evening bimatoprost vs vehicle for 16 weeks. The bimatoprost group showed a 25% increase in eyelash length, 106% increase in fullness, and 18% increase in darkness from baseline — significantly greater than vehicle on all measures. The clinical effect requires continuous use; eyelashes return to baseline within 8–16 weeks of discontinuation.

Allergan’s US patent on bimatoprost expired in 2014. Generic bimatoprost ophthalmic solutions are now available globally. Sun Pharmaceutical Industries Ltd’s Careprost is among the most widely distributed bimatoprost products globally, manufactured in Sun’s WHO-GMP-certified facilities.

TL;DR comparison table

How bimatoprost works on eyelashes

Bimatoprost is a synthetic structural analog of prostaglandin F2α, with high affinity for prostaglandin F (FP) receptors. The mechanism for eyelash growth involves:

1. Prolonged anagen phase: like minoxidil for scalp hair, bimatoprost extends the active growth phase of the hair cycle. Eyelashes normally cycle through anagen (1–6 months), catagen, and telogen; bimatoprost lengthens anagen specifically.
2. Increased follicle density (number of hairs in anagen): a greater proportion of eyelash follicles are in active growth at any given time on bimatoprost, producing visible fullness.
3. Increased melanogenesis in eyelash matrix: stimulation of melanocyte activity in the eyelash follicle, producing darker hair shafts.

The cosmetic effect is reversible — eyelashes return to baseline within 8–16 weeks of discontinuation. Continuous nightly use is required to maintain effect.

Bioequivalence

Both Latisse and Careprost contain bimatoprost ophthalmic solution at the same FDA-recognised 0.03% concentration in identical excipients (benzalkonium chloride preservative, sodium chloride, citric acid, sodium phosphate buffers). The molecule and formulation are pharmacologically and pharmaceutically identical. Generic bimatoprost ophthalmic solutions in US retail since 2014 are FDA Orange Book AB-rated. Careprost, manufactured by Sun Pharma under WHO-GMP, is among the most widely distributed bimatoprost products globally; Sun is one of the largest WHO-GMP-certified ophthalmic manufacturers and supplies multiple national procurement programs.

How to apply (technique matters)

Standard nightly application:

1. Remove eye makeup and contact lenses. Wash face with mild cleanser. Dry hands.
2. Place one drop of solution on the disposable applicator (sterile single-use brush).
3. Apply the solution along the upper eyelid lash line, from inner to outer canthus. Avoid the lower eyelid — bimatoprost migrates well in tears and produces sufficient lower-lid effect from the upper application alone.
4. Wipe any excess solution that runs onto the surrounding skin (forehead, cheek) to prevent unintended hair growth in those areas.
5. Dispose of the applicator. Use a fresh applicator on the other eye to prevent cross-contamination.
6. Reinsert contact lenses no sooner than 15 minutes after application.

Technique matters because bimatoprost runs onto adjacent skin readily and produces local hyperpigmentation and hypertrichosis (unwanted hair growth) at the skin where it lands. Careful application along the lash line only avoids these effects.

Price comparison

Side effects

The bimatoprost side-effect profile applies across all supply chains:¹

• Eye irritation, redness, or itching (~4–8%) — usually mild, related to benzalkonium chloride preservative
• Eyelid skin hyperpigmentation (~3–4%) — darkening of the skin where the solution contacts; usually reversible with discontinuation but takes months
• Iris pigmentation darkening (~<1% at the eyelash dose, much higher at the glaucoma intraocular dose) — permanent change in eye colour, only in mixed-colour irises (hazel, green-brown). Pure blue or brown eyes are not affected.
• Hypertrichosis of upper cheek or forehead — if solution runs off lash line. Reversible with technique correction and discontinuation.
• Conjunctival hyperaemia (red eye) — ~3% transient

The iris-pigmentation effect is the principal long-term consideration. It is rare at the cosmetic eyelash dose (which is approximately 1/40th of the daily intraocular bimatoprost exposure from the glaucoma drop), but the change is permanent if it occurs. Users with mixed-colour irises should be informed of the risk before starting.

Contraindications

Manufacturer disclosure: who makes Careprost?

Careprost is manufactured by Sun Pharmaceutical Industries Ltd, headquartered in Mumbai — one of the largest WHO-GMP-certified ophthalmic manufacturers globally. Sun holds approvals from US FDA, UK MHRA, WHO Prequalification, and most national regulatory bodies. Per-batch finished-product release for Careprost includes HPLC content assay for bimatoprost concentration, preservative concentration verification, particulate matter testing, sterility testing per USP <71>, and pH testing. Certificates of Analysis are available on request through MedsBase customer support — provide order ID and the batch number from your packaging.

How to order Careprost from MedsBase

Careprost ships worldwide from MedsBase in discreet packaging. Payment via crypto (USDT, BTC, ETH via Plisio), credit card via a regulated crypto on-ramp (statement descriptor is the on-ramp provider name — a regulated card-payment processor — never MedsBase), or SEPA where available. See our credit card payment guide. Orders are covered by the MedsBase Reshipment Assurance Policy. Browse the Careprost product page.

Who should choose Careprost over Latisse?

• Long-term cosmetic users: cosmetic eyelash treatment is a multi-year commitment for users who want to maintain the effect — the difference between $200/month and $10/month compounds to $2,300/year savings.
• Users without US dermatology access: Latisse is prescribed through US dermatology/med-spa channels and requires an in-person evaluation. Careprost via MedsBase ships worldwide.
• Users who want flexibility on bottle size: Careprost is available in larger 3 mL bottle formats and multi-bottle packs — useful for users planning longer treatment runs.

For other cosmetic-eye products and skincare topical treatments, browse the MedsBase beauty & skin care category.

Pricing context: The brand-vs-generic price comparison on this page is one entry in MedsBase’s broader Brand-vs-Generic Medication Pricing Index — a quarterly-updated reference covering 15 brand-vs-generic pairs across ED, GLP-1, hair-loss, PrEP, and cosmetic clusters, with full methodology and citation disclosure.

Frequently Asked Questions

Is Careprost literally the same drug as Latisse?

Yes. Both contain bimatoprost 0.03% ophthalmic solution at the same FDA-recognised concentration in identical excipients (benzalkonium chloride preservative, buffers, pH-adjusted to physiologic range). The mechanism, onset, response rate, and side-effect profile are pharmacologically and pharmaceutically identical. The differences are the manufacturer and the price.

Is Careprost FDA-approved?

No. Careprost is not registered with the US FDA because it is not marketed in the United States as a cosmetic product. However, Sun Pharmaceutical manufactures Careprost under WHO-GMP certification. Generic bimatoprost products that ARE sold in US pharmacies (since 2014) are FDA Orange Book AB-rated and therapeutically equivalent to Latisse.

How long until I see eyelash improvement?

Visible improvement begins at approximately week 4–8. Full effect (length, fullness, darkness) is generally achieved by week 16. This timeline is intrinsic to the eyelash hair cycle and applies equally to Careprost and Latisse.

What happens if I stop using bimatoprost?

Eyelashes gradually return to baseline within 8–16 weeks of discontinuation. Continuous nightly application is required to maintain the cosmetic effect — there is no “cure” window.

What about the eye-colour-change risk?

Permanent iris pigmentation darkening occurs in less than 1 percent of users at the cosmetic eyelash dose, primarily in mixed-colour irises (hazel, green-brown). Pure blue or pure brown eyes are not affected. The risk is meaningfully higher when bimatoprost is used at the glaucoma intraocular dose (one drop per eye nightly directly into the eye) than at the cosmetic dose (applied externally to lash line). If you have mixed-colour irises and want to be cautious, this is a real consideration before starting.

Can I use the glaucoma drop (Lumigan) for eyelashes?

Pharmacologically the molecule is identical. Lumigan is dosed for direct intraocular application; Latisse and Careprost are dosed and packaged for upper-lid application. Some users substitute Lumigan applied externally with technique modifications, but the bottle isn’t designed for that use and dose precision suffers. Stick with the eyelash-formulation product.

Should I apply to both upper and lower lash lines?

No. Apply only to the upper lash line. Bimatoprost migrates well in tear film and produces sufficient lower-lid effect from upper application alone. Direct lower-lid application increases the rate of unwanted side effects (skin hyperpigmentation, hypertrichosis on cheek).

How is Careprost so much cheaper than Latisse?

Two reasons. First, the Latisse branded price reflects the prescription-channel distribution markup (dermatology offices and med-spas), in-person visit requirement, and Allergan/AbbVie’s marketing infrastructure. Second, Sun Pharma manufactures bimatoprost at substantial scale for both the cosmetic eyelash market and the glaucoma market globally. The molecule itself is inexpensive to produce; the price difference reflects the distribution and marketing infrastructure of the US prescription-cosmetic channel.

Sources

1. Yoelin S, Walt JG, Earl M. Safety, effectiveness, and subjective experience with topical bimatoprost 0.03% for eyelash growth. Dermatologic Surgery. 2010;36(5):638–649.
2. US Food and Drug Administration. NDA 022369, Latisse (bimatoprost). Approval letter, 24 December 2008.
3. Sun Pharmaceutical Industries Ltd. WHO-GMP certification under the Indian Central Drugs Standard Control Organisation; multiple national regulatory approvals (US FDA, UK MHRA, EMA, WHO PQ).

Last clinically reviewed: 18 May 2026.

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.